| 1. |
Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int, 2017, 11(4): 317-370.
|
| 2. |
中華人民共和國國家衛生健康委員會醫政醫管局. 原發性肝癌診療規范 (2019年版). 臨床肝膽病雜志, 2020, 36(2): 277-292.
|
| 3. |
中國醫師協會肝癌專業委員會. 肝細胞癌合并門靜脈癌栓多學科診治中國專家共識 (2018年版). 臨床肝膽病雜志, 2019, 35(4): 737-743.
|
| 4. |
Zhou C, Yao Q, Zhang H, et al. Combining transcatheter arterial embolization with iodized oil containing apatinib inhibits HCC growth and metastasis. Sci Rep, 2020, 10(1): 2964. doi: 10.1038/s41598-020-59746-1.
|
| 5. |
中國抗癌協會肝癌專業委員會轉化治療協作組. 肝癌轉化治療中國專家共識 (2021版). 中華消化外科雜志, 2021, 20(6): 600-616.
|
| 6. |
Wang Z, Peng Y, Hu J, et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: a single center study of 45 patients. Ann Surg, 2020, 271(3): 534-541.
|
| 7. |
Sandstr?m P, R?sok BI, Sparrelid E, et al. ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: results from a scandinavian multicenter randomized controlled trial (LIGRO Trial). Ann Surg, 2018, 267(5): 833-840.
|
| 8. |
Cai X, Tong Y, Yu H, et al. The ALPPS in the treatment of hepatitis B-related hepatocellular carcinoma with cirrhosis: a single-center study and literature review. Surg Innov, 2017, 24(4): 358-364.
|
| 9. |
Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol, 2021, 22(7): 977-990.
|
| 10. |
Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: a pilot study. Hepatol Res, 2014, 44(5): 523-531.
|
| 11. |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 2018, 391(10126): 1163-1173.
|
